Pharma & Biotech Global Week in Review 21 September 2011 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

US: Federal Circuit denies petition for rehearing in AMP v. USPTO (Patent Docs)

Patent issues precede UN high level meet on NCDs (Spicy IP) (IP Watch)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

NCDs pose major threat to public health, WHO reports (IP Watch)

Patent issues precede UN high level meet on NCDs (Spicy IP) (IP Watch)

How to cure the distribution channel of pharmaceuticals which includes counterfeit products (IP Dragon)

Canada: Proposed revisions to PM(NOC) Regulations aim to reduce redundancy (IP Osgoode)

Europe: Hopes rise for a bright future, if the court gets it right for paediatric SPC extensions… (The SPC blog)

Europe: Novartis mystery case heads for ECJ: can anyone help? Novartis AG v Actavis UK Limited (The SPC blog) (The SPC blog)

Europe: Note on recent ECJ Memantine and Galantamine rulings (The SPC blog)

US: Federal Circuit denies petition for rehearing in AMP v. USPTO (Patent Docs)

US: Federal Circuit denies plaintiff(s)’ petition for rehearing in AMP v. USPTO (Patent Docs)

US: Deciphering the patent-eligibility message in Prometheus, Myriad and Classen (Patent Docs)

US: Biotech/pharma patent issuances increased 39% in 2010 (Patent Docs)

Vietnam cables: Data exclusivity should be automatic, comprehensive, retroactive and without procedures and formalities (KEI)

 

Products

Actos (Pioglitazone) – US: Takeda files patent infringement complaint against Accord Healthcare in response to Para IV certification (Patent Docs)

Atorvastatin – EU: Polymorphs in the field of pharmaceutical drug development: T-0777/08 (JIPLP)

Avodart (Dutasteride), Jalyn (Dutasteride, Tamsulosin) – US: GlaxoSmithKline files patent infringement suit against Mylan and Impax following Para IV certification filing (Patent Docs) (GenericsWeb)

Coreg (Carvedilol) – US: Flamel Technologies files patent infringement complaint against Anchen Pharmaceuticals in response to Para IV certification (Patent Docs)

Myfortic (Mycophenolate) – US: Novartis files patent infringement complaint against Accord Healthcare following Para IV certification filing (Patent Docs)

Nexavar (Sorafenib) – India: Natco’s compulsory licence: Professional negligence? (Spicy IP)

Nuvigil (Armodafinil) – US: Cephalon files patent infringement complaint against Sandoz following Para IV certification (Patent Docs)

Zemplar (Paricalcitol) – US: Abbott Laboratories files patent infringement complaint against Hospira in response to Para IV certification filing (Patent Docs)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 20,533 other followers

%d bloggers like this: